Crohn’s disease may be a lifelong condition, but today, there are an abundance of effective treatments that can help bring ...

Unfortunately, IBD, as well as treatment, have both steadily increased in the last few years. Specifically, Crohn’s disease affects up to 300 people for every 100,000 in North America. Individuals of ...

For many people with Crohn’s disease, reaching remission—when inflammation is no longer detectable—seems like a major victory ...

Early treatment of pediatric Crohn's disease with anti-tumor necrosis factor medications can substantially reduce the risk of ...

2024 — Scientists uncovered an overlooked mechanism in the gut immune system of patients suffering from severe cases of Crohn's disease. The discovery may help define how to treat patients with ...

Lutikizumab is under clinical development by AbbVie and currently in Phase II for Crohn's Disease (Regional Enteritis).

A new study published recently in the journal Gut shows children with Crohn's who were prescribed anti-TNF (tumor necrosis ...

MetroCreative Inflammatory bowel disease (IBD) affects between 2.4 and 3.1 million people across the United States, according ...

Zinpentraxin alfa is under clinical development by F. Hoffmann-La Roche and currently in Phase I for Crohn's Disease (Regional Enteritis).

Nutrients specific to the Mediterranean diet could help with symptom management in inflammatory bowel disease, evidence ...

About 40,000 children in the U.S. suffer from Crohn's disease, a chronic inflammatory ... pricier than other anti-inflammatory drugs used to treat Crohn's like azathioprine and methotrexate ...